Risk-adjusted patent expiry dates which incorporate litigation probability differ meaningfully from nominal expiry dates, and sophisticated investors and competitors work with risk-adjusted numbers when modeling competitive scenarios
Unless one of the new pipeline drugs shows another differentiator like alzheimer protection, or becomes combined with something like a myostatin inhibitor that can protect muscle-mass loss, then I believe were going to see the semaglutide patent release cause a nosedive for every other branded GLP-1 on the market in 2032
[197] This increase in extracellular glutamate presumably occurs via the amphetamine-induced internalization of EAAT3, a glutamate reuptake transporter in some dopamine and norepinephrine neurons
10.1152/ajpcell.00001.2016 10 FreitasR.MartinsA.SilvaJ.AlvesC.PinteusS.AlvesJ.et al (2020)
Long-Term Use One common question patients have is how long can someone take a GLP-1 medication
Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB et al